{
    "clinical_study": {
        "@rank": "34964", 
        "arm_group": [
            {
                "arm_group_label": "(R)(T)", 
                "arm_group_type": "Active Comparator", 
                "description": "Period 1: Fimasartan 60mg \u2192 Period 2: Fimasartan 30mg"
            }, 
            {
                "arm_group_label": "(T)(R)", 
                "arm_group_type": "Active Comparator", 
                "description": "Period 1: Fimasartan 30mg \u2192 Period 2: Fimasartan 60mg"
            }
        ], 
        "brief_summary": {
            "textblock": "Open-label, randomized, crossover clinical trials for single oral dose of 60mg fimasartan\n      and single IV infusion of 30mg fimasartan to evaluate the absolute bioavailability of\n      Kanarb\u00ae tablet (fimasartan) in healthy subjects"
        }, 
        "brief_title": "Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb\u00ae Tablet (Fimasartan) in Healthy Subjects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age: 20 - 55 years\n\n          -  body weight: standard weight(Broca's index, Possible range is plus or minus\n             20percent)\n\n          -  written informed consent\n\n        Exclusion Criteria:\n\n          -  known allergy to Fimasartan\n\n          -  existing cardiac or hematological diseases\n\n          -  existing hepatic and renal diseases\n\n          -  existing gastrointestinal diseases\n\n          -  acute or chronic diseases which could affect drug absorption or metabolism history of\n             any serious psychological disorder\n\n          -  abnormal diet which could affect drug absorption or metabolism\n\n          -  positive drug or alcohol screening\n\n          -  smokers of 10 or more cigarettes per day\n\n          -  participation in a clinical trial during the last 90 days prior to the start of the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671020", 
            "org_study_id": "A657-BR-CT-115"
        }, 
        "intervention": [
            {
                "arm_group_label": "(R)(T)", 
                "description": "Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg", 
                "intervention_name": "Fimasartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "(T)(R)", 
                "description": "Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg", 
                "intervention_name": "Fimasartan", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "fimasartan", 
            "absolute bioavailability"
        ], 
        "lastchanged_date": "August 22, 2012", 
        "location": {
            "contact": {
                "email": "phshinjg@gmail.com", 
                "last_name": "Jae Gook Shin, Ph.D", 
                "phone": "82-51-890-0603"
            }, 
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Inje University Busan Paik Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Open-label, Randomized, Crossover Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb\u00ae Tablet (Fimasartan) in Healthy Subjects", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "AUCinf, AUC, Cmax, Tmax, half-life; t1/2z, AUCt, Vdss, Cl,", 
            "safety_issue": "Yes", 
            "time_frame": "PO : 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48hr, IV : 0.25, 0.5, 0.75, 1, 1.08, 1.17, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48hr"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671020"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boryung Pharmaceutical Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boryung Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}